Pharmaceutical Executive November 2014

November 2014 | Volume 0, Issue 0
The science of drug discovery is back on script—and the stars are cued up for a new generation of breakthrough therapies. But is pharma ready to raise its game and cut a deal with all those "prove it to me" payers?
By Pharmaceutical Executive Editors
By rethinking the role of the sales rep and the new skills it demands, pharma companies can put themselves in a prime competitive position.
Jesper Hoiland, Novo Nordisk's President for North America, assesses the challenges and opportunities during his first year at the helm of the diabetes franchise leader's biggest affiliate market.
From the Editor
Amid a resurgence in drug development for hard-to-treat conditions, the bigger question is whether the times are as good for the industry tasked with rendering basic science into therapeutically effective medicines.
By Pharmaceutical Executive Editors
Agency's plan for reporting clinical trial data has sparked strong reactions from health campaigners, industry, and patients.
Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge.
By Pharmaceutical Executive Editors
The rush to digital will continue at a fast clip, but marketers need to reacquaint themselves with their brands' audiences.
Treatment Action Group (TAG) reaches a milestone in improving access to much-needed treatments for tuberculosis.
lorem ipsum